Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
Rüter
Björn
B
Wijermans
Pierre
P
Claus
Rainer
R
Kunzmann
Regina
R
Lübbert
Michael
M
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002897:Chromosomes, Human, Pair 7; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007958:Leukocyte Count; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine